Comparable efficacy-safety and better renal function with everolimus and reduced-exposure tacrolimus versus standard-exposure tacrolimus in liver transplant recipients: H2304 and H2307 pooled analysis

被引：0

作者：

Levy, G. ^{[1
]}

Lee, S. G. ^{[2
]}

Jeng, L. -B ^{[3
]}

Soin, A. S. ^{[4
]}

Lee, W. -C ^{[5
]}

De Simone, P. ^{[6
]}

Nevens, F. ^{[7
]}

Suh, K. -S ^{[8
]}

Fischer, L. ^{[9
]}

Joo, D. J. ^{[10
]}

Fung, J. ^{[11
]}

Joh, J. -W ^{[12
]}

Kaido, T. ^{[13
]}

Grant, D. ^{[14
]}

Meier, M. ^{[15
]}

Sips, C. ^{[15
]}

Kaneko, S. ^{[16
]}

Saliba, F. ^{[17
]}

机构：

[1] Univ Toronto, Toronto, ON, Canada

[2] Asan Med Ctr, Seoul, South Korea

[3] China Med Univ Hosp, Taichung, Taiwan

[4] Medic Hosp, Medanta, Gurgaon, India

[5] Chang Gung Mem Hosp, Taoyuan, Taiwan

[6] Azienda Osped Univ Pisana, Pisa, Italy

[7] Univ Hosp Gasthuisberg, Leuven, Belgium

[8] Seoul Natl Univ, Coll Med, Seoul, South Korea

[9] Univ Med Ctr Eppendorf, Hamburg, Germany

[10] Yonsei Univ, Coll Med, Seoul, South Korea

[11] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[12] Samsung Med Ctr, Seoul, South Korea

[13] Kyoto Univ Hosp, Kyoto, Japan

[14] Toronto Gen Hosp, Toronto, ON, Canada

[15] Novartis Pharma AG, Basel, Switzerland

[16] Novartis Pharma KK, Tokyo, Japan

[17] Hop Paul Brousse, Villejuif, France

来源：

TRANSPLANTATION | 2019年 / 103卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

O-059

引用

页码：36 / 36

页数：1

共 47 条

[21] Everolimus with Reduced Tacrolimus Exposure Versus Standard Tacrolimus in Hepatitis C Virus Positive De Novo Liver Transplant Recipients.
Saliba, F.
De Simone, P.
De Carlis, L.
Metselaar, H. J.
Beckebaum, S.
Jonas, S.
Sudan, D.
Fung, J.
Fischer, L.
Huang, M. A.
Wang, Y.
Sips, C.
Lopez, P.
Nevens, F.
LIVER TRANSPLANTATION, 2012, 18 : S98 - S98
[22] Everolimus with Early Reduction or Elimination of Tacrolimus in 719 De Novo Liver Transplant Recipients-12 Month Efficacy and Safety Results from H2304 Study
Fung, J.
Nevens, F.
De Carlis, L.
Metselaar, H. J.
Beckebaum, S.
Saliba, F.
Jonas, S.
Sudan, D.
Fischer, L.
Duvoux, C.
Chavin, K. D.
Koneru, B.
Jiang, H.
Hexham, J. M.
Junge, G.
De Simone, P.
AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 28 - 28
[23] Everolimus Safety Profile in Liver Transplant Recipients With 3-Year Exposure in the H2304 Core and Extension Study.
Saliba, F.
Rogiers, X.
Chapman, W.
Caicedo, L.
Alsina, A.
Teperman, L.
Junge, G.
Rauer, B.
Dong, G.
De Simone, P.
LIVER TRANSPLANTATION, 2014, 20 : S247 - S248
[24] EVEROLIMUS-BASED IMMUNOSUPPRESSION PROVIDES SUPERIOR RENAL FUNCTION AND COMPARABLE EFFICACY VERSUS STANDARD TACROLIMUS IN DE NOVO LIVER TRANSPLANTATION: 3-YEAR RESULTS FROM H2304 STUDY EXTENSION
Saliba, F.
Kaiser, G. M.
De Carlis, L.
Metselaar, H. J.
De Simone, P.
Duvoux, C.
Nevens, F.
Fischer, L.
Fung, J.
Dong, G.
Rauer, B.
Junge, G.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S362 - S362
[25] EVEROLIMUS WITH REDUCED TACROLIMUS PROVIDES IMPROVED RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS: A MELD SCORE SUBGROUP ANALYSES FROM THE RANDOMISED-CONTROLLED H2304 STUDY AT MONTH 12 AND 24
Saliba, Faouzi
Fischer, Lutz
De Simone, Paolo
Dong, Gaohong
Escrig, Cesar
Lopez, Patricia
TRANSPLANT INTERNATIONAL, 2015, 28 : 199 - 200
[26] Evolution of Renal Function with Early Everolimus-Facilitated Reduction or Elimination of Tacrolimus in 719 De Novo Liver Transplant Recipients: 12 Month Data of the H2304 Study
De Simone, P.
Nevens, F.
De Carlis, L.
Metselaar, H. J.
Beckebaum, S.
Saliba, F.
Jonas, S.
Sudan, D.
Fischer, L.
Duvoux, C.
Foltys, D.
Koneru, B.
Wang, Y.
Hexham, J. M.
Junge, G.
Fung, J.
AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 238 - 238
[27] Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor: Results from the TRANSFORM Study
Oppenheimer, Federico
Russ, Graeme
Viklicky, Ondrej
Oberbauer, Rainer
Garcia, Valter
Witzke, Oliver
Kuypers, Dirk
Danguilan, Romina
Das Gupta, Ayan
Bernhardt, Peter
Sommerer, Claudia
TRANSPLANTATION, 2018, 102 : S363 - S363
[28] Efficacy and Safety of Everolimus with Reduced-Exposure Tacrolimus and Corticosteroid Withdrawal in De Novo Pediatric Renal Transplant Recipients: 12-Month Results from the CRADLE Study
Ettenger, R.
Tonshoff, B.
Tedesco, H.
Dello Strologo, L.
Marks, S.
Pape, L.
Martzloff, E.
Rauer, B.
Ng, J.
Lopez, P.
AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 407 - 408
[29] Impact of Early Everolimus-Facilitated Reduction or Elimination of Tacrolimus on the Evolution of Renal Function in 719 De Novo Liver Transplant Recipients: 12 Month Data of the H2304 Study
Metselaar, H. J.
Saliba, F.
Schemmer, P.
Foltys, D.
Fabregat, J.
Ericzon, B. -G.
Dong, G.
Hexham, J. M.
Junge, G.
De Simone, P.
TRANSPLANTATION, 2012, 94 (10) : 44 - 44
[30] EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED TACROLIMUS IN LIVING-DONOR LIVER TRANSPLANT RECIPIENTS WITH HEPATOCELLULAR CARCINOMA: SUBGROUP ANALYSIS FROM THE H2307-STUDY (NCT01888432)
Settmacher, U.
Braun, F.
Lopez, P. M.
Kochuparampil, J.
Lieb, S.
TRANSPLANT INTERNATIONAL, 2017, 30 : 27 - 27

← 1 2 3 4 5 →